Practical Considerations for Dose Selection in Pediatric Patients to Ensure Target Exposure Requirements-Reference-Cited by-同舟云学术

Practical Considerations for Dose Selection in Pediatric Patients to Ensure Target Exposure Requirements

Published:2014-05-20 Issue:4 Volume:16 Page:749-755
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Barbour April M.,Fossler Michael J.,Barrett Jeffrey

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

http://link.springer.com/content/pdf/10.1208/s12248-014-9603-x.pdf

Reference11 articles.

1. Holford N. Dosing in children. Clin Pharmacol Ther. 2010;87(3):367–70.

2. Food and Drug Administration. Guidance for Industry: General Consideration for Peidatric Pharmacokinetics Studies for Drugs and Biological Products. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072114.pdf .

3. Anderson GD, Lynn AM. Optimizing pediatric dosing: a developmental pharmacologic approach. Pharmacotherapy. 2009;29(6):680–90.

4. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25–36.

5. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30(5):329–32.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Evaluation of Ontogeny Functions of the Major UDP‐Glucuronosyltransferase Enzymes to Underwrite Physiologically Based Pharmacokinetic Modeling in Pediatric Populations;The Journal of Clinical Pharmacology;2024-06-19

2. Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma;Neuro-Oncology;2024-04-01

3. Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis;Clinical Infectious Diseases;2024-02-10

4. Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis;Clinical Infectious Diseases;2023-01-04

5. Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric Extrapolation;Therapeutic Innovation & Regulatory Science;2022-09-03